Investigational MS Drug Safe, Effective at 18 Months
The potent, once-daily oral BTK inhibitor tolebrutinib showed encouraging safety and efficacy results in patients with multiple sclerosis through 72 weeks in a new long-term extension of a phase 2b trial.
United States Jeffrey Cohen University Of Toronto Barlo Ms Program At St Mellen Center Americas Committee For Treatment
Source: medscape.com